AlphaQuest’s Tarsus Pharmaceuticals TARS Stock Holding History

AlphaQuest’s Portfolio TARS Stock Details TARS Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	–	Sell	-19,193	Closed	-$1.57M	–	1850
2025 Q4	$1.57M	Buy	19,193 +3,618	+23%	+$270K	0.09%	258
2025 Q3	$926K	Sell	15,575 -5,061	-25%	-$249K	0.06%	463
2025 Q2	$836K	Buy	20,636 +16,964	+462%	+$763K	0.08%	375
2025 Q1	$189K	Buy	+3,672	New	+$182K	0.02%	1026
2024 Q4	–	Sell	-504	Closed	-$16.6K	–	2007
2024 Q3	$16.6K	Sell	504 -1,751	-78%	-$49.2K	﹤0.01%	1519
2024 Q2	$61.3K	Buy	+2,255	New	+$75.8K	0.01%	1041

Other funds holding TARS

DTC

Deep Track Capital Greenwich, Connecticut $6.87B AUM 205.24% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

RTW Investments New York $11.7B AUM 174.13% 1-Year Est. Return

PBA

Paradigm Biocapital Advisors New York $5.34B AUM 380.18% 1-Year Est. Return

Janus Henderson Group London $209B AUM 37.72% 1-Year Est. Return

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Jennison Associates New York $167B AUM 44.17% 1-Year Est. Return

Assenagon Asset Management Senningerberg, Luxembourg $80.2B AUM 50.56% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.55T AUM 33.47% 1-Year Est. Return

AlphaQuest's TARS Position: Q1 2026 in Review

AlphaQuest sold out of Tarsus Pharmaceuticals (TARS) in Q1 2026, closing a stake of 19,193 shares — an estimated $1.57M sold.

AlphaQuest first reported a position in TARS in Q2 2024 and held it in 6 quarters. The position peaked at $1.57M in Q4 2025. 253 funds tracked by Wall St. Rank hold TARS as of Q1 2026.

AlphaQuest reported no remaining Tarsus Pharmaceuticals position as of Q1 2026 after selling out during the quarter.
AlphaQuest sold 19,193 Tarsus Pharmaceuticals shares in Q1 2026, an estimated $1.57M.
AlphaQuest first reported a position in Tarsus Pharmaceuticals in Q2 2024 and held it in 6 quarters.
AlphaQuest's Tarsus Pharmaceuticals position peaked at $1.57M in Q4 2025.
253 funds tracked by Wall St. Rank held Tarsus Pharmaceuticals as of Q1 2026.

Based on AlphaQuest's 13F filing for Q1 2026.